Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting now
Conditions studied: Chronic Granulomatous Disease (CGD)
In brief
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Key facts
- Study ID
- NCT06605378
- Run by
- Ensoma
- People needed
- 60
- Starts
- 2024-11-18
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2026-03-03
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is ≤5% (i.e., the percentage of dihydrorhodamine-positive [DHR+] cells is ≤5% by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
- The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
- The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).
You may not qualify if…
- The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
- The participant is unable to comply with the sample collection procedure based on investigator judgment.
Where it is running
- Home-based telemedicine — Phoenix, Arizona, United States (enrolling)
- Home-based telemedicine — Little Rock, Arkansas, United States (enrolling)
- Home-based telemedicine — Sacramento, California, United States (enrolling)
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- Home-based telemedicine — Denver, Colorado, United States (enrolling)
- Home-based telemedicine — Hartford, Connecticut, United States (enrolling)
- Home-based telemedicine — Dover, Delaware, United States (enrolling)
- Home-based telemedicine — Washington D.C., District of Columbia, United States (enrolling)
- Home-based telemedicine — Tallahassee, Florida, United States (enrolling)
- Home-based telemedicine — Atlanta, Georgia, United States (enrolling)
- Home-based telemedicine — Boise, Idaho, United States (enrolling)
- Home-based telemedicine — Springfield, Illinois, United States (enrolling)
- Home-based telemedicine — Indianapolis, Indiana, United States (enrolling)
- Home-based telemedicine — Des Moines, Iowa, United States (enrolling)
- Home-based telemedicine — Topeka, Kansas, United States (enrolling)
- Home-based telemedicine — Frankfort, Kentucky, United States (enrolling)
- Home-based telemedicine — Baton Rouge, Louisiana, United States (enrolling)
- Home-based telemedicine — Augusta, Maine, United States (enrolling)
- Home-based telemedicine — Annapolis, Maryland, United States (enrolling)
- Home-based telemedicine — Boston, Massachusetts, United States (enrolling)
- Home-based telemedicine — Lansing, Michigan, United States (enrolling)
- Home-based telemedicine — Saint Paul, Minnesota, United States (enrolling)
- Home-based telemedicine — Jackson, Mississippi, United States (enrolling)
- Home-based telemedicine — Jefferson City, Missouri, United States (enrolling)
- Home-based telemedicine — Montgomery, Alabama, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.